Last September, a 44-year-old software engineer named Kevin in Austin ordered both versions of CJC-1295 from a compounding pharmacy before realizing he had no idea which one to use. "My provider said 'CJC-1295, once daily at bedtime,' but the vial I got said DAC on the label," he told me over email. "I almost injected a week's worth of peptide in a single nightly dose." His confusion isn't unusual. The two versions of CJC-1295 share a name but almost nothing else pharmacokinetically, and the half-life difference is the whole ballgame.
Here's the short version: CJC-1295 with DAC has a half-life of roughly 6 to 8 days. CJC-1295 without DAC (Modified GRF 1-29) has a half-life of roughly 30 minutes. One you inject weekly. The other you inject daily. Mix them up and you either get zero signal or way too much of it. CJC-1295 is not FDA-approved. It is a compounded research peptide dispensed by licensed pharmacies for individual patients. Individual results vary.
What Half-Life Actually Means (and Why 7 Minutes Was the Problem)
Half-life is the time it takes for plasma concentration to drop to half its peak value. Simple enough. But the reason CJC-1295 exists at all comes down to one brutal number: natural GHRH, the hormone your hypothalamus releases to trigger growth hormone secretion, has a half-life of about 7 minutes. It gets chewed up by enzymes almost the moment it enters the bloodstream.
That made early GHRH-based therapies a logistics nightmare. You'd need an IV drip or constant injections to maintain any meaningful signal. So researchers started modifying the molecule. Swapping out a few amino acids in the GHRH(1-29) fragment got the half-life up to around 30 minutes. That's Modified GRF 1-29, the "no-DAC" version. A genuine improvement, but still a peptide you need to inject at least once a day.
Then ConjuChem developed the DAC modification (Drug Affinity Complex), which lets the peptide bind to circulating albumin in your blood. Albumin is a protein your body recycles slowly, so anything hitching a ride on it sticks around. The result: a half-life of 6 to 8 days. Think of it like the difference between tossing a paper airplane and strapping a note to a carrier pigeon. Same message, wildly different delivery timelines.
The published characterization by Teichman SL et al. (2006) confirmed sustained elevation of GH and IGF-1 across multiple days from a single injection, making once-weekly dosing viable.
The Decay Curves, Side by Side
Numbers make this concrete.
CJC-1295 with DAC (single injection):
- Day 0: peak concentration
- Day 6 to 8: approximately 50% of peak
- Day 12 to 16: approximately 25% of peak
- Day 18 to 24: approximately 12% of peak
CJC-1295 without DAC (single injection):
- Minute 0: peak concentration
- Minute 30: approximately 50% of peak
- Minute 60: approximately 25% of peak
- Minute 120: approximately 6% of peak
- Minute 180: essentially cleared
The DAC version leaves a long, slow tail of signaling. The no-DAC version spikes and vanishes like a camera flash. Both can raise GH and IGF-1 meaningfully over the course of a week, but they do it through completely different kinetic patterns.
How Half-Life Dictates Your Dosing Schedule
DAC schedules take advantage of that persistent signal:
Get provider-reviewed GLP-1 therapy
Side effects are manageable with the right support. A licensed provider can adjust your dose when you need it.
Start Free Assessment →- Once weekly: 1 to 2 mg in a single subcutaneous injection
- Twice weekly: 0.5 to 1 mg per injection, spaced 3 to 4 days apart
Twice-weekly dosing smooths out the plasma concentration curve a bit. Once weekly is simpler. Most people pick simplicity.
No-DAC schedules work around the rapid clearance:
- Once daily: typically pre-bed (to coincide with natural GH secretion during sleep)
- Twice daily: pre-bed plus post-workout or fasted morning
- Three times daily: all three windows
The boring truth is that the no-DAC version requires genuine habit-building. If you can't commit to a daily injection, DAC is the more practical choice from a compliance standpoint.
Stacking, Cycling, and Missed Doses
Stacking with Ipamorelin. This is where half-life becomes a practical consideration beyond just scheduling. No-DAC CJC-1295 and ipamorelin both have short half-lives (30 minutes and roughly 2 hours, respectively). Same syringe, same timing, same nightly ritual. It's the most common peptide stack for a reason: it's easy.
DAC plus ipamorelin is a different animal. The DAC signal is sustained throughout the week; ipamorelin provides acute daily pulses layered on top of that baseline. Two separate injection schedules, two separate rhythms. Workable, but less elegant.
Cycling off. Here's where the half-life difference really matters. Stop no-DAC and the signal is gone within hours. Clean break. Stop DAC and you're looking at roughly 2 weeks before the peptide fully clears, which means any planned off-cycle needs to account for that tail. A 4-week "off" period with DAC is really more like 2 weeks off plus 2 weeks of fading signal.
Missed doses. DAC gives you a buffer. Miss your Monday injection by a day or two? Take it late. Miss it by three or more days? Skip it and pick up your next scheduled dose. No-DAC offers no such forgiveness. Miss a dose, move on. Don't double up to compensate.
The Longevity Argument for Short Half-Life
I think this is the most interesting wrinkle in the entire CJC-1295 conversation, and it's the reason a growing subset of longevity-focused clinicians prefer the no-DAC version despite the hassle of daily injections.
The logic goes like this: your body releases growth hormone in pulses, not as a steady drip. Short-acting GHRH analogs mimic that pulsatile pattern. DAC, with its days-long signal, does not. Some researchers flag sustained IGF-1 elevation as potentially less favorable for aging markers compared to pulsatile patterns. And there's a theoretical concern (still debated) that receptors downregulate faster under continuous stimulation.
None of this is settled science. But it's a reasonable enough concern that plenty of patients willingly trade convenience for a signaling pattern that looks more like what their body would produce on its own at age 25.
Side Effects and Reversibility
Short half-life means short side effects. If no-DAC CJC-1295 gives you flushing, water retention, or an exaggerated hunger spike, those symptoms typically resolve within hours of stopping.
DAC is less forgiving. Any side effects ride the same 6-to-8-day decay curve as the therapeutic signal. Stop injecting and you're still waiting 1 to 2 weeks for near-complete clearance. For someone who's never tried a GHRH analog before, that's an argument for starting with the no-DAC version: if something feels wrong, you can bail quickly.
How CJC-1295 Compares to Other Peptides
| Peptide | Half-Life |
|---|---|
| Natural GHRH | ~7 minutes |
| Sermorelin | 10 to 20 minutes |
| Modified GRF 1-29 (no-DAC CJC-1295) | ~30 minutes |
| Tesamorelin | ~26 minutes |
| Ipamorelin | ~2 hours |
| CJC-1295 with DAC | 6 to 8 days |
The DAC version is an outlier by an absurd margin. Every other GHRH analog on that list operates in minutes to hours. That's exactly why it exists, and exactly why confusing it with the no-DAC version can cause real problems.
Common Misunderstandings Worth Clearing Up
- "DAC is stronger." No. It's longer-acting. Potency per molecule at the receptor is a separate question from how long the molecule hangs around.
- "No-DAC is weaker." Also no. It just clears fast, which means you need more frequent dosing to get comparable weekly exposure.
- "I can substitute one for the other at the same dose." Absolutely not. The dosing is orders of magnitude different.
- "Half-life equals the duration of the GH pulse." The GH pulse triggered by either version is much shorter than the peptide's own half-life. The peptide is the signal; the GH release is the response. Different clocks.
FAQ
Does longer half-life mean more potent?
No. Half-life describes duration in circulation, not the strength of GH release per molecule. DAC lasts longer but doesn't hit harder per unit time.
Can I make no-DAC last longer by injecting a bigger dose?
No. Clearance rate is independent of dose. A larger injection produces a bigger GH pulse, but the peptide still clears in roughly the same timeframe.
How long after stopping CJC-1295 does it fully clear?
DAC: roughly 2 to 4 weeks for near-complete clearance (4 to 5 half-lives). No-DAC: hours to about a day.
Does the half-life difference affect IGF-1 patterns?
Yes. DAC produces sustained IGF-1 elevation across days. No-DAC produces pulsatile IGF-1 elevation, with levels rising and falling around each injection. Cumulative weekly exposure may be comparable, but the pattern is distinct.
Why does this matter for my daily routine?
For DAC users, a Sunday evening injection fits easily into a weekly rhythm. For no-DAC users, peptide prep becomes a nightly habit, typically at bedtime. The commitment level is different, and that matters for long-term adherence.
Is one version "better" than the other?
Depends entirely on your goals, your tolerance for daily injections, and whether your clinician prioritizes pulsatile vs. sustained signaling. There's no universal winner.
Related Reading
---
Disclaimer: CJC-1295 is not FDA-approved. It is a compounded research peptide dispensed by licensed pharmacies for individual patients under a valid prescription. This article is for educational purposes and does not constitute medical advice. Individual results vary. Always consult a licensed prescribing clinician before starting any compounded peptide protocol.
Citation: Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.